IHEEZO™ Unveils New Horizons in Ocular Care with Health Canada Approval

Apotex Expands Ocular Care with Approval of IHEEZO™

On May 26, 2026, Apotex Inc., the foremost pharmaceutical company in Canada, announced a significant milestone: the approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel 3%) by Health Canada. This new topical anesthetic is specifically designed for use during ophthalmologic procedures, ensuring pain-free care for adult patients.

IHEEZO™: A Revolutionary Product

The introduction of IHEEZO™ represents a critical advancement in ocular medicine. This innovative gel formulation is both sterile and preservative-free, packaged in convenient single-use vials. The regulated administration is to be conducted solely by qualified eye care professionals, emphasizing patient safety and healthcare standards. This step not only underscores Apotex’s dedication to enhancing clinical practices but also addresses the pressing needs of healthcare practitioners across the nation.

Martin Arès, President of Apotex Canada and Rest of World, stated, "This approval reflects our commitment to supporting Canadian healthcare professionals with high-quality medicines that meet important clinical needs." With IHEEZO™, Apotex aims to bolster its growing portfolio in ocular care, which already includes well-regarded products like Verkazia®, Clobivis™, and Aflivu, an aflibercept biosimilar.

A Commitment to Quality and Innovation

Apotex prides itself on being a driver of innovation in the healthcare sector. Established with the goal of improving access to affordable and innovative medications, the company has made significant contributions to various therapeutic areas. The approval of IHEEZO™ is a testament to Apotex's mission to enhance healthcare delivery and outcome for patients while supporting clinical professionals' efforts.

The company’s headquarters in Toronto serves as a central hub for its global operations, with additional offices in the U.S., Mexico, and India. Apotex is recognized as the largest Canadian-based pharmaceutical manufacturer, providing a diverse range of generic and branded drugs that cater to millions worldwide.

Future Directions for Ocular Care

Healthcare professionals are encouraged to review the complete Product Monograph for in-depth information regarding dosing, administration, potential warnings, and any adverse effects related to IHEEZO™. Apotex's commitment does not end with the launch of this product; rather, it marks a starting point for an expanded focus on ocular health and other significant healthcare needs in Canada and beyond.

In summary, the approval of IHEEZO™ not only enhances Apotex's reputation in ocular care but also signifies a major improvement in patient comfort during essential medical procedures. With ongoing development and the introduction of new medicines, Apotex continues to play a pivotal role in shaping the future of healthcare in Canada.

For more information about their comprehensive portfolio, visit Apotex's official website.